Even as boom wanes, a new $200M SPAC is still hop­ing for an­oth­er big score

The biotech sec­tor has been boom­ing through­out the Covid-19 pan­dem­ic — and while it has slowed down con­sid­er­ably, there are yet more SPACs at work.

Blank check com­pa­ny Bio­Plus Ac­qui­si­tion Corp an­nounced last Thurs­day that it priced its up­sized IPO of 20 mil­lion units at $10.00 per unit — for $200 mil­lion.

The SPAC start­ed trad­ing on Fri­day at $10.02 un­der the tick­er $BIO­SU.

Bio­Plus didn’t wade in­to de­tails about its tar­gets, say­ing on­ly that it planned to merge with “Life Sci­ences Sec­tor,” ac­cord­ing to the com­pa­ny’s S-1 filed back in Ju­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER